Tesaro Inc. (NASDAQ:TSRO) had its price objective boosted by equities research analysts at RBC Capital Markets to $128.00 in a research note issued on Monday. RBC Capital Markets’ price objective suggests a potential upside of 28.95% from the company’s previous close.

Several other research firms have also recently weighed in on TSRO. Mizuho reiterated an “outperform” rating and set a $67.00 price objective on shares of Tesaro in a research report on Thursday, June 30th. Lake Street Capital restated a “buy” rating and issued a $114.00 price target on shares of Tesaro in a report on Tuesday, September 6th. FBR & Co restated a “buy” rating on shares of Tesaro in a report on Thursday, June 30th. Wells Fargo & Co. restated an “outperform” rating on shares of Tesaro in a report on Thursday, June 30th. Finally, Zacks Investment Research upgraded shares of Tesaro from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Tesaro presently has an average rating of “Buy” and a consensus target price of $102.69.

Analyst Recommendations for Tesaro (NASDAQ:TSRO)

Shares of Tesaro (NASDAQ:TSRO) opened at 99.26 on Monday. The company has a 50-day moving average of $96.42 and a 200 day moving average of $68.96. The company’s market capitalization is $5.10 billion. Tesaro has a 52-week low of $29.51 and a 52-week high of $110.48.

Tesaro (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.71) by $0.43. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. The company earned $36.60 million during the quarter, compared to analysts’ expectations of $4.98 million. During the same period in the prior year, the company posted ($1.51) earnings per share. Analysts predict that Tesaro will post ($7.36) earnings per share for the current year.

In other news, SVP Martin H. Jr. Huber sold 408 shares of the business’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $108.12, for a total value of $44,112.96. Following the sale, the senior vice president now owns 1,250 shares of the company’s stock, valued at $135,150. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Edward C. English sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $88.54, for a total transaction of $619,780.00. Following the completion of the sale, the vice president now directly owns 3,500 shares in the company, valued at approximately $309,890. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in shares of Tesaro by 13.3% in the first quarter. BlackRock Inc. now owns 7,096 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 834 shares in the last quarter. BlackRock Group LTD boosted its position in shares of Tesaro by 7.9% in the first quarter. BlackRock Group LTD now owns 162,499 shares of the biopharmaceutical company’s stock valued at $7,154,000 after buying an additional 11,880 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of Tesaro by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,293,906 shares of the biopharmaceutical company’s stock valued at $56,971,000 after buying an additional 23,384 shares in the last quarter. State Street Corp boosted its position in shares of Tesaro by 0.7% in the first quarter. State Street Corp now owns 893,749 shares of the biopharmaceutical company’s stock valued at $39,349,000 after buying an additional 6,026 shares in the last quarter. Finally, Pictet Asset Management Ltd. boosted its position in shares of Tesaro by 35.8% in the first quarter. Pictet Asset Management Ltd. now owns 55,000 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 14,500 shares in the last quarter. 88.81% of the stock is currently owned by institutional investors.

About Tesaro

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Stock Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related stocks with our FREE daily email newsletter.